Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06732245 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Aug 15, 2026 to Aug 15, 2027
    • Start date: Mar 15, 2025 to Aug 15, 2026
    • Study completion date: Dec 15, 2026 to Dec 15, 2027
    • Site details revised at 17 of 17 sites
    v3
  2. Site details revised at 17 of 17 sitesv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A phase 2 study to assess the efficacy of NA-931 alone or in addition to Tirzepatide to assess efficacy and safety in overweight or obese men and women
Trial Details
NCT Number NCT06732245
Lead Sponsor Biomed Industries, Inc.
Collaborators: Bioneurals Ltd
Conditions
(from sponsor)		 Obesity and Overweight
Related terms Obesity, Overweight
Enrollment 224 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov